(Q46558044)

English

First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

scientific article published in August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

0 references

1 reference

based on heuristic

inferred from title

author name string

Abdelkefi A

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Torjman L

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Ben Romdhane N

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Ladeb S

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

El Omri H

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Ben Othman T

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Elloumi M

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Bellaj H

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Lakhal A

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Jeddi R

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Aissaouï L

11

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Saad A

12

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Hsaïri M

13

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Boukef K

14

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Dellagi K

15

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Ben Abdeladhim A

16

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

Bone Marrow Transplantation

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

36

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

193-198

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705050

0 references

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Angiogenesis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide: a novel template for anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide and dexamethasone combination for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide and dexamethasone for resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Bone marrow angiogenesis and progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

21 January 2018

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors influencing platelet recovery after blood cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705050

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705050

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

release_24mgcyodunfqrpj7ujhmx42rwy

1 reference

https://api.fatcat.wiki/v0/release/24mgcyodunfqrpj7ujhmx42rwy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/15968290

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46558044&oldid=2118137958"